NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro
D-Cycloserine (DCS) is a broad-spectrum antibiotic that is currently FDA-approved to treat tuberculosis (TB) disease and urinary tract infection (UTI). Despite numerous reports showing good clinical efficacy, DCS fell out of favor as a UTI treatment because of its propensity to cause side effects. N...
Saved in:
Main Authors: | Michael T. Sapko (Author), Michael Manyak (Author), Riccardo Panicucci (Author), Jonathan C. Javitt (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antipsychotic treatments; Focus on lurasidone
by: Tomiki eSumiyoshi
Published: (2013) -
Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis
by: Mwila Mulubwa, et al.
Published: (2019) -
In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Tsung-Ying Yang, et al.
Published: (2021) -
Clinical potential of lurasidone in the management of schizophrenia
by: Samalin L, et al.
Published: (2011) -
Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine
by: Steven M. LeVine, et al.
Published: (2022)